MARKET

XBIT

XBIT

XBiotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.13
-0.39
-2.88%
Opening 14:36 11/22 EST
OPEN
13.61
PREV CLOSE
13.52
HIGH
14.24
LOW
12.99
VOLUME
201.34K
TURNOVER
--
52 WEEK HIGH
15.32
52 WEEK LOW
3.661
MARKET CAP
539.20M
P/E (TTM)
-20.5317
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XBIT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XBIT News

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
  • Benzinga.2d ago
  • XBiotech Highlights Rapid Enrollment For Randomized Multi-Center Study For Bermekimab In Patients with Hidradenitis Suppurativa
  • Benzinga.3d ago
  • XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa
  • GlobeNewswire.3d ago

More

Industry

Biotechnology & Medical Research
+1.70%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About XBIT

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
More

Webull offers XBiotech Inc (XBIT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.